Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891909783> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W2891909783 abstract "11591 Background: Amplification of the mesenchymal-epithelial transition ( MET) proto-oncogene or phosphatidylinositol3-kinase ( PI3K) is common in non-small-cell lung cancer (NSCLC) and represents a potential therapeutic target. NSCLC with coexisting driver mutations or amplifications is a cause of great concern. Methods: From 2013 until now, fluorescence in situ hybridization was used to screen for MET amplified NSCLC patients.The amplification of the MET was defined as centromere 7 ratio ≥ 2.0 and the criterion of Cappuzzi. The amplification of the PIK3CA was copy numbers ≥ 4.0. We established the patient-derived exnograft (PDX) mouse model from a dual MET/PIK3CA-amplified patient. Preclinical efficacy of single versus dual inhibition was evaluated in vivo. Six groups were allocated to receive the treatment of vehicle control, bozitinib,crizotinib, taselisib (PI3K inhibitor), bozitinib+taselisib, or crizotinib+taselisib, respectively. Results: Totally, 568 (568/2321, 24.47%) patients harbored positive MET amplification and 6 (6/568,1%) were comfirmed with dual MET/PI3K amplification. The two stageⅣ patients received MET inhibitor treatment.One trial (NCT02896231) patient was treated with bozitinib and achieved confirmed PR, but with 3 months PFS and 5 months OS. The best response was PR and PFS was 5.6 months for the other one receiving the study drug capmatinib (NCT02276027). In the PDX mouse model experiment, we found three single-anget inhibitors monotherapy to be active but only transiently effective in controlling the growth of PDX. The PDX models showed more sensitivity to taselisib among the three single-anget groups. In contrast, the combination of the two inhibitors caused a stronger and long-lasting growth inhibition in PDX models. The addition of taselisib to bozitinib or crizotinib monotherapy provided obvious enhanced activity. Regretfully, two mice died because of the toxicities in the crizotinib+taselisib group. Conclusions: Patients with dual MET/PIK3CA amplification represent a rare molecular subtype of NSCLC and have a relatively short duration of response to MET inhibitors.The combination of MET/PI3K inhibitors is synergistic preclinically." @default.
- W2891909783 created "2018-09-27" @default.
- W2891909783 creator A5010968379 @default.
- W2891909783 creator A5016050402 @default.
- W2891909783 creator A5043568223 @default.
- W2891909783 creator A5045345910 @default.
- W2891909783 creator A5074151953 @default.
- W2891909783 creator A5075426616 @default.
- W2891909783 creator A5083650470 @default.
- W2891909783 date "2017-05-20" @default.
- W2891909783 modified "2023-09-26" @default.
- W2891909783 title "Co-amplification of MET and PIK3CA in NSCLC and data on a PDX mouse model." @default.
- W2891909783 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.11591" @default.
- W2891909783 hasPublicationYear "2017" @default.
- W2891909783 type Work @default.
- W2891909783 sameAs 2891909783 @default.
- W2891909783 citedByCount "0" @default.
- W2891909783 crossrefType "journal-article" @default.
- W2891909783 hasAuthorship W2891909783A5010968379 @default.
- W2891909783 hasAuthorship W2891909783A5016050402 @default.
- W2891909783 hasAuthorship W2891909783A5043568223 @default.
- W2891909783 hasAuthorship W2891909783A5045345910 @default.
- W2891909783 hasAuthorship W2891909783A5074151953 @default.
- W2891909783 hasAuthorship W2891909783A5075426616 @default.
- W2891909783 hasAuthorship W2891909783A5083650470 @default.
- W2891909783 hasConcept C126322002 @default.
- W2891909783 hasConcept C143998085 @default.
- W2891909783 hasConcept C502942594 @default.
- W2891909783 hasConcept C71924100 @default.
- W2891909783 hasConceptScore W2891909783C126322002 @default.
- W2891909783 hasConceptScore W2891909783C143998085 @default.
- W2891909783 hasConceptScore W2891909783C502942594 @default.
- W2891909783 hasConceptScore W2891909783C71924100 @default.
- W2891909783 hasLocation W28919097831 @default.
- W2891909783 hasOpenAccess W2891909783 @default.
- W2891909783 hasPrimaryLocation W28919097831 @default.
- W2891909783 hasRelatedWork W1576497688 @default.
- W2891909783 hasRelatedWork W1839975169 @default.
- W2891909783 hasRelatedWork W1850419181 @default.
- W2891909783 hasRelatedWork W2042103473 @default.
- W2891909783 hasRelatedWork W2139810669 @default.
- W2891909783 hasRelatedWork W2152931798 @default.
- W2891909783 hasRelatedWork W2234716123 @default.
- W2891909783 hasRelatedWork W2330239550 @default.
- W2891909783 hasRelatedWork W2330501746 @default.
- W2891909783 hasRelatedWork W2522698104 @default.
- W2891909783 hasRelatedWork W2537306989 @default.
- W2891909783 hasRelatedWork W2603803880 @default.
- W2891909783 hasRelatedWork W2620079993 @default.
- W2891909783 hasRelatedWork W2767236761 @default.
- W2891909783 hasRelatedWork W2890870241 @default.
- W2891909783 hasRelatedWork W2897570808 @default.
- W2891909783 hasRelatedWork W2911422134 @default.
- W2891909783 hasRelatedWork W2997712450 @default.
- W2891909783 hasRelatedWork W3176315669 @default.
- W2891909783 hasRelatedWork W3214554089 @default.
- W2891909783 isParatext "false" @default.
- W2891909783 isRetracted "false" @default.
- W2891909783 magId "2891909783" @default.
- W2891909783 workType "article" @default.